Advertisement
Home Tags Stents

Tag: Stents

For patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

In STEMI, Biodegradable Polymer Sirolimus-Eluting Stents Superior

Stents superior to durable polymer everolimus-eluting stents for end point of target lesion failure at one year
For older patients with acute myocardial infarction

PCI Beneficial for All Categories of Older AMI Patients

PCI linked to improved survival versus medical therapy for young-old, middle-old, and old-old patients
A preliminary analysis has revealed a "potentially concerning signal" of increased long-term mortality risk with paclitaxel-coated products indicated for peripheral arterial disease

FDA Issues Update on Mortality Risk With Paclitaxel-Coated Products

Preliminary analyses revealed approximately 50 percent increased risk at five-year follow-up
The U.S. Food and Drug Administration alerted health care providers on Thursday that the agency is investigating the use of paclitaxel-coated balloons and paclitaxel-eluting stents to treat peripheral arterial disease in the femoropopliteal artery because of a potentially increased mortality risk in the long term.

FDA Investigating Paclitaxel-Coated Balloons, Paclitaxel-Eluting Stents

Investigation triggered by meta-analysis showing possible increased mortality in PAD patients at 2 years
Unprotected left main percutaneous coronary intervention (PCI) procedures represented less than 1 percent of all PCIs in clinical practice in the United States from 2009 through 2016

Volumes Low for Unprotected Left Main PCI

Real-world procedures performed on older, comorbid patients, lead to more adverse events
There are few significant differences in target-vessel failure with different types of second-generation drug-eluting stents for obstructive left main coronary artery disease

Second-Gen Drug-Eluting Stents Similarly Effective for LMCAD

Only one significant between-group difference in three-year risk of target-vessel failure for left main CAD
The odds of carotid artery stenting have increased in the post-Carotid Revascularization Endarterectomy vs Stenting Trial era

Odds for Carotid Artery Stenting in Seniors Up Post-CREST Era

Increase in odds of receiving CAS in all patients older than 70 years and in symptomatic women
Everolimus-eluting bioresorbable vascular scaffolds are associated with increased odds of scaffold thrombosis and other thrombotic events compared with everolimus-eluting metallic stents

Thrombosis Odds Up With Bioresorbable Vascular Scaffolds

BVSs linked to increased risk of MI, target lesion revascularization and failure versus metallic stents
There is a strong relationship between high on-clopidogrel platelet reactivity and two-year ischemic and bleeding outcomes after drug-eluting stent implantation

High Platelet Reactivity Tied to Ischemic, Bleeding Outcomes

Findings based on two-year follow-up after drug-eluting stent implantation
Sildenafil-coated stents appear to cut a patient's odds for clots

Sildenafil-Coated Stent May Help Prevent Clots, Stenosis

In animal study, sildenafil showed potential in reducing both restenosis and blood clot formation